• J. Thorac. Cardiovasc. Surg. · Sep 2024

    Clinical Effectiveness of Genetic Testing Guidelines in Patients with Thoracic Aortic Aneurysms.

    • Ely Erez, Acuna HigakiAdrian RARDivision of Cardiac Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut., Michela Cupo, Tuan Anh Phu, Shiv Verma, Roland Assi, and Prashanth Vallabhajosyula.
    • Division of Cardiac Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut.
    • J. Thorac. Cardiovasc. Surg. 2024 Sep 23.

    ObjectiveTo analyze the effectiveness of the current genetic testing guidelines for patients with thoracic aortic aneurysms (TAA).MethodsWe evaluated thoracic aortic disease (TAD) genetic tests from 2012 to 2023 in patients aged 18 and older with a thoracic aorta diameter greater than 4 cm. Mutation rates were compared by ACC/AHA testing criteria met by patients: age under 60, syndromic features of connective tissue diseases (CTD), family history, or none. Results were classified as pathogenic, variants of uncertain significance (VUS) or negative. Genes tested were analyzed in two categories: primary (strongly associated with heritable diseases) or secondary (less strongly associated).Results1034 patients were included: 42.4% aged under 60, 19.1% with syndromic features of CTD, 41.8% with family history, and 30.7% meeting no criteria. Overall, 3.97% had pathogenic mutations and 27.27% had VUS. Mutation rates were highest in patients with syndromic features of CTD (13.2%), followed by patients aged under 60 (5.48%), family history (4.63%), and no criteria met (2.21%). Primary genes had pathogenic mutation rates of 3.29% and VUS rates of 12.19%. Secondary genes had lower pathogenic rates (0.68%) but higher VUS (17.5%). Mutation rates in primary genes peaked at 22% in patients meeting all criteria, whereas those under 60 years without family history or syndromic features of CTD had the lowest rate (0.54%).ConclusionsRefining genetic testing guidelines to incorporate multiple patient criteria could enhance risk stratification and support informed decision-making in TAD genetic testing. Limiting testing to genes strongly associated with TAD could lower VUS rates.Copyright © 2024. Published by Elsevier Inc.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.